Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2016

View Archived Issues

vTv Therapeutics describes HK-2 inhibitors

SAMHD1, a novel biomarker for cytarabine response and therapeutic target in AML

Ebola vaccine rVSV-ZEBOV shows promising results in clinical trial

Pharmacyclics patents BTK inhibitors

Merck & Co. and MSD R&D disclose PDE2A inhibitors

OncoMed Pharmaceuticals reports phase Ia results on OMP-305B83

Scientists report phase II data for selinexor in patients with MM

Investigators present preliminary phase II results of SL-401 in AML patients

BAX-930 shows potential in patients with hereditary thrombotic thrombocytopenic purpura

Columbia University Medical Center sponsors clinical study using Biocept's liquid biopsy platform

FDA expands indications for Shire's Adynovate

NIPTE forms part of a newly announced National Biopharmaceutical Manufacturing Institute

Prana offers update on development portfolio

Bioinformatics confirms GM6 as a regulator of ALS- and AD- relevant pathways

DynPort Vaccine Company receives contract to help advance medical products for NIAID

Capnia and Essentialis sign merger agreement

World's only recombinant monovalent acellular Pertussis vaccine receives Thai FDA approval

Anthera reports topline data from phase III study of Sollpura

FDA puts clinical hold on several early-stage trials of vadastuximab talirine

OSE Immunotherapeutics signs worldwide license option agreement with Servier for Effi-7

U.S. and China IND clearances for Ascentage's APG-1252

Ono seeks Japanese approval of Opdivo in gastric cancer

Phase III results for padeliporfin vascular-targeted photodynamic therapy in prostate cancer

Immunomedics' phase II study of sacituzumab govitecan reaches planned enrollment

Escend Pharmaceuticals' tetrandrine gets FDA orphan designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...